Journal
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 328, Issue 18, Pages 1849-1861Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/jama.2022.19590
Keywords
-
Categories
Funding
- National Institutes of Health (NIH)
- 2017 ACC/AHA High Blood Pressure GuidelineWriting Committee
- AHA Scientific Statement on Resistant Hypertension
- Endocrine Society Clinical Practice Guideline on Primary Aldosteronism Panel
- National Institutes of Health
Ask authors/readers for more resources
Hypertension, affecting approximately 116 million adults in the US and more than 1 billion adults worldwide, is a leading cause of cardiovascular disease morbidity and mortality. First-line therapy for hypertension involves lifestyle modifications such as weight loss, reduced sodium intake and increased potassium supplementation, healthy dietary patterns, physical activity, and limited alcohol consumption. When medication is necessary, first-line therapies include thiazide or thiazidelike diuretics, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and calcium channel blockers.
ImportanceHypertension, defined as persistent systolic blood pressure (SBP) at least 130 mm Hg or diastolic BP (DBP) at least 80 mm Hg, affects approximately 116 million adults in the US and more than 1 billion adults worldwide. Hypertension is associated with increased risk of cardiovascular disease (CVD) events (coronary heart disease, heart failure, and stroke) and death. ObservationsFirst-line therapy for hypertension is lifestyle modification, including weight loss, healthy dietary pattern that includes low sodium and high potassium intake, physical activity, and moderation or elimination of alcohol consumption. The BP-lowering effects of individual lifestyle components are partially additive and enhance the efficacy of pharmacologic therapy. The decision to initiate antihypertensive medication should be based on the level of BP and the presence of high atherosclerotic CVD risk. First-line drug therapy for hypertension consists of a thiazide or thiazidelike diuretic such as hydrochlorothiazide or chlorthalidone, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker such as enalapril or candesartan, and a calcium channel blocker such as amlodipine and should be titrated according to office and home SBP/DBP levels to achieve in most people an SBP/DBP target (<130/80 mm Hg for adults <65 years and SBP <130 mm Hg in adults >= 65 years). Randomized clinical trials have established the efficacy of BP lowering to reduce the risk of CVD morbidity and mortality. An SBP reduction of 10 mm Hg decreases risk of CVD events by approximately 20% to 30%. Despite the benefits of BP control, only 44% of US adults with hypertension have their SBP/DBP controlled to less than 140/90 mm Hg. Conclusions and RelevanceHypertension affects approximately 116 million adults in the US and more than 1 billion adults worldwide and is a leading cause of CVD morbidity and mortality. First-line therapy for hypertension is lifestyle modification, consisting of weight loss, dietary sodium reduction and potassium supplementation, healthy dietary pattern, physical activity, and limited alcohol consumption. When drug therapy is required, first-line therapies are thiazide or thiazidelike diuretics, angiotensin-converting enzyme inhibitor or angiotensin receptor blockers, and calcium channel blockers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available